Jan. 29, 2014
Sarah P. Payne
See more on Sarah P. PayneSullivan & Cromwell LLP | Palo Alto | Corporate
Among them, she advised on the acquisition of Onyx Pharmaceuticals Inc. by client Amgen Inc. for $10.4 billion.
Payne had to manage many different aspects of the deal as it unfolded.
In late June, she made a private, unsolicited bid on behalf of Amgen for Onyx, a San Francisco-based biopharmaceutical company focused on therapies for the treatment of cancer.
Onyx rejected...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In